Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasurgratinib succinate - Eisai Co Ltd

Next Previous
Drug Profile

Tasurgratinib succinate - Eisai Co Ltd

Alternative Names: E-7090; TASFYGO

Latest Information Update: 30 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Class Amides; Amines; Antineoplastics; Benzene derivatives; Ethers; Indoles; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer
  • Phase II Cholangiocarcinoma; Solid tumours
  • Phase I HER2 negative breast cancer

Most Recent Events

  • 18 Jun 2026 Eisai completes a phase I trial in HER2-negative breast cancer (Monotherapy, Combination therapy, Metastatic disease, Recurrent) in Japan (PO, Tablet) (NCT04572295)
  • 28 May 2026 Tasurgratinib succinate is still in phase I development for HER2-negative-breast-cancer(Combination therapy, Metastatic disease, Recurrent) in Japan (PO, Tablet) (Eisai pipeline, May 2026)
  • 28 May 2026 Tasurgratinib succinate is still in phase-I development for HER2-negative-breast-cancer(Metastatic disease, Monotherapy, Recurrent) in Japan (PO, Tablet) (Eisai pipeline, May 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top